Actively Recruiting
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
Led by First Affiliated Hospital of Chongqing Medical University · Updated on 2025-06-04
30
Participants Needed
1
Research Sites
136 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.
CONDITIONS
Official Title
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years of age
- Signed informed consent
- Patients with suspected, newly diagnosed, or previously diagnosed malignant disease with PSMA or FAP positive expression, supported by MRI, CT, or pathology report
You will not qualify if you...
- Patients with non-malignant disease
- Patients who are pregnant
- Inability or unwillingness to provide written informed consent
- Known or expected hypersensitivity to 68Ga-PSFA or its components
- Any serious medical condition or circumstance that may interfere with study procedures or evaluations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016
Actively Recruiting
Research Team
X
Xiaoyang Zhang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here